These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 38732145)

  • 21. A unique mode of nucleic acid immunity performed by a multifunctional bacterial enzyme.
    Bari SMN; Chou-Zheng L; Howell O; Hossain M; Hill CM; Boyle TA; Cater K; Dandu VS; Thomas A; Aslan B; Hatoum-Aslan A
    Cell Host Microbe; 2022 Apr; 30(4):570-582.e7. PubMed ID: 35421352
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phage Against the Machine: Discovery and Mechanism of Type V Anti-CRISPRs.
    Marino ND
    J Mol Biol; 2023 Apr; 435(7):168054. PubMed ID: 36934807
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CRISPR-Cas-Mediated Phage Resistance Enhances Horizontal Gene Transfer by Transduction.
    Watson BNJ; Staals RHJ; Fineran PC
    mBio; 2018 Feb; 9(1):. PubMed ID: 29440578
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Revenge of the phages: defeating bacterial defences.
    Samson JE; Magadán AH; Sabri M; Moineau S
    Nat Rev Microbiol; 2013 Oct; 11(10):675-87. PubMed ID: 23979432
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Discovery, Mechanisms, and Evolutionary Impact of Anti-CRISPRs.
    Borges AL; Davidson AR; Bondy-Denomy J
    Annu Rev Virol; 2017 Sep; 4(1):37-59. PubMed ID: 28749735
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BacteRiophage EXclusion (BREX): A novel anti-phage mechanism in the arsenal of bacterial defense system.
    Chaudhary K
    J Cell Physiol; 2018 Feb; 233(2):771-773. PubMed ID: 28444888
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Biology of CRISPR-Cas: Backward and Forward.
    Hille F; Richter H; Wong SP; Bratovič M; Ressel S; Charpentier E
    Cell; 2018 Mar; 172(6):1239-1259. PubMed ID: 29522745
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Why put up with immunity when there is resistance: an excursion into the population and evolutionary dynamics of restriction-modification and CRISPR-Cas.
    Gurney J; Pleška M; Levin BR
    Philos Trans R Soc Lond B Biol Sci; 2019 May; 374(1772):20180096. PubMed ID: 30905282
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evolutionary Dynamics between Phages and Bacteria as a Possible Approach for Designing Effective Phage Therapies against Antibiotic-Resistant Bacteria.
    Hasan M; Ahn J
    Antibiotics (Basel); 2022 Jul; 11(7):. PubMed ID: 35884169
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-CRISPRs go viral: The infection biology of CRISPR-Cas inhibitors.
    Li Y; Bondy-Denomy J
    Cell Host Microbe; 2021 May; 29(5):704-714. PubMed ID: 33444542
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Unveil the Secret of the Bacteria and Phage Arms Race.
    Wang Y; Fan H; Tong Y
    Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901793
    [TBL] [Abstract][Full Text] [Related]  

  • 32. My host's enemy is my enemy: plasmids carrying CRISPR-Cas as a defence against phages.
    Siedentop B; Rüegg D; Bonhoeffer S; Chabas H
    Proc Biol Sci; 2024 Jan; 291(2015):20232449. PubMed ID: 38262608
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Landscape of New Nuclease-Containing Antiphage Systems in Escherichia coli and the Counterdefense Roles of Bacteriophage T4 Genome Modifications.
    Wang S; Sun E; Liu Y; Yin B; Zhang X; Li M; Huang Q; Tan C; Qian P; Rao VB; Tao P
    J Virol; 2023 Jun; 97(6):e0059923. PubMed ID: 37306585
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting of temperate phages drives loss of type I CRISPR-Cas systems.
    Rollie C; Chevallereau A; Watson BNJ; Chyou TY; Fradet O; McLeod I; Fineran PC; Brown CM; Gandon S; Westra ER
    Nature; 2020 Feb; 578(7793):149-153. PubMed ID: 31969710
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-CRISPR proteins as a therapeutic agent against drug-resistant bacteria.
    Vyas P; Harish
    Microbiol Res; 2022 Apr; 257():126963. PubMed ID: 35033831
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Systematic discovery of antiphage defense systems in the microbial pangenome.
    Doron S; Melamed S; Ofir G; Leavitt A; Lopatina A; Keren M; Amitai G; Sorek R
    Science; 2018 Mar; 359(6379):. PubMed ID: 29371424
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Meet the Anti-CRISPRs: Widespread Protein Inhibitors of CRISPR-Cas Systems.
    Hwang S; Maxwell KL
    CRISPR J; 2019 Feb; 2(1):23-30. PubMed ID: 31021234
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bacteriostatic antibiotics promote CRISPR-Cas adaptive immunity by enabling increased spacer acquisition.
    Dimitriu T; Kurilovich E; Łapińska U; Severinov K; Pagliara S; Szczelkun MD; Westra ER
    Cell Host Microbe; 2022 Jan; 30(1):31-40.e5. PubMed ID: 34932986
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cooperation between Different CRISPR-Cas Types Enables Adaptation in an RNA-Targeting System.
    Hoikkala V; Ravantti J; Díez-Villaseñor C; Tiirola M; Conrad RA; McBride MJ; Moineau S; Sundberg LR
    mBio; 2021 Mar; 12(2):. PubMed ID: 33785624
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bacteriophage T4 Escapes CRISPR Attack by Minihomology Recombination and Repair.
    Wu X; Zhu J; Tao P; Rao VB
    mBio; 2021 Jun; 12(3):e0136121. PubMed ID: 34154416
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.